LAS VEGAS, NV / ACCESSWIRE / October 29, 2015 / The last time Propanc Health Group, Inc. set up a pattern like this it hit a high of $0.134. A run to that price again would represent a 211% gain. So it's worth examining how likely that is to occur again. A brief look at their latest press could shed some light on the potential for another massive bull run: Propanc Raises First $1.2 Million of Potential $4 Million Deal. The aggregate deal size will be sufficient to cover current and future research and development activities leading up to the preparation and commencement of human trials for their lead product, PRP.
This is just the latest in a long run of impressive news that has been helping this company's investors continually realize massive profits over the past year.
And it could be the spark that creates a similar rally in PPCH's share price which is why we're urging investors to take a very close look at Propanc Health Group, Inc. Although, judging by recent activity it doesn't look like the company is having trouble finding eager backers betting on this company's future.
Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancers. Propanc have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc's products involve or employ proenzymes, which are inactive precursors of enzymes.
Propanc isn't the only lower priced biotech seeing major interest. Another Biotechnology stock under $2 a share worth a long look is PrimaBioMed Ltd. (PMBD), the company has just raised $1MM through a private placement which will be used to fund Prima's IMP321 clinical trial program.
According to The Street PMBD "recently formed a double bottom chart pattern, after shares found some buying interest at $1.15 to $1.14 a share. Following that bottom, shares of Prima Biomed have now started to spike higher above those support levels and it's quickly moving within range of triggering a near-term breakout trade. That breakout will trigger if this stock manages to take out some key near-term overhead resistance levels at $1.41 to $1.48 with high volume."
Biotechnology stocks have been on a 12 month tear, however, not all news has been great in the biotech sector. Some leaders that have been great for investors in the past have fallen on hard times which might bring more investment into upstarts like Propanc and PrimaBioMed.
Genocea Biosciences, Inc. (GNCA) had been one of this year's darlings reaching a high of $16. GNCA discovers and develops immunotherapies using a transformational technology platform for T Cell antigen discovery. Unfortunately, GNCA has had a disastrous set of results from its recent trials causing shares to plummet. Biotech investors should monitor for a point where the stock becomes oversold, in conjunction with some form of hopeful news from the company.
Another Biotech that has recently fallen on hard times is Zafgen, Inc. (ZFGN) as an investigation is under way concerning the Company's and its officers' possible violations of federal securities laws. This comes on the heels of a death during clinical trials involving beloranib, a drug designed to reduce hunger while stimulating the use of stored fat as an energy source. While it's not clear if the company is at fault, it is clear investors are seeing huge losses.
These two stocks certainly illustrate the risk involved in the sector, but savvy investors have begun to realize if you're going to take a risk on a volatile sector like biotech, it would be smart to look at lower priced options such as PPCH and PMBD. Gains in these lower priced stocks tend to reward investors with much higher returns as evidenced by their moves already this year.
In conclusion, it looks like the biotech sector can continue to make major gains for investors, but it will be the upstarts that lead the way.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns, Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For this press release ACR Communication, LLC. has been compensated $6,000 by Propanc Health Group, Corp. we expect to be compensated an additional $20,000 by the company.
Contact:
SOURCE: ACR Communication, LLC
